BIIB122 (LUMA) LRRK2 Inhibitor for Parkinson's Disease
Overview
Mermaid diagram (expand to render)
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
The LUMA trial (NCT05348785) represents one of the most advanced clinical programs for a disease-modifying therapy in Parkinson's disease. BIIB122 (formerly DNL151) is a potent, selective, oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) developed by Biogen in collaboration with Denali Therapeutics. The trial is specifically designed to evaluate whether inhibiting LRRK2 kinase activity can slow the progression of early-stage Parkinson's disease["@biogen2022"].
Parkinson's disease affects approximately 10 million people worldwide, representing one of the most significant unmet medical needs in modern medicine. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options. Current treatments provide symptomatic relief but do not address the underlying neurodegenerative process["@parkinsons2023"].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05348785 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Biogen |
| Enrollment | 650 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2022-04-19 00:00:00 |
| Completion Date | 2026-03-09 00:00:00 |
| Last Updated | 2025-10-23 00:00:00 |
Conditions Studied
Scientific Background
Disease Context
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability, as well as non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction[@parkinsons2023].
Pathologically, PD is characterized by the loss of dopaminergic [neurons](/cell-types/dopaminergic-neurons-snpc) in the substantia nigra pars compacta and the presence of Lewy bodies, which are intracellular inclusions composed primarily of [alpha-synuclein](/proteins/alpha-synuclein) protein. Current treatments provide symptomatic relief but do not halt disease progression.
LRRK2 Biology in Parkinson's Disease
LRRK2 (Leucine-Rich Repeat Kinase 2) is a large multi-domain protein with intrinsic kinase activity. Pathogenic variants in the LRRK2 gene, particularly the G2019S variant, are among the most common genetic causes of familial PD and also contribute to sporadic disease risk.
The LRRK2 protein consists of multiple functional domains:
- Kinase domain: The enzymatic core that phosphorylates substrate proteins
- ROC-COR domain: A GTPase domain that regulates kinase activity
- Ankyrin, leucine-rich repeat, and WD40 domains: Protein-protein interaction domains
All pathogenic LRRK2 mutations increase kinase activity by two- to threefold, leading to hyperphosphorylation of downstream substrates[@steger2016].
LRRK2 Pathogenic Mechanisms
LRRK2 hyperactivity leads to:
Impaired autophagy-lysosomal pathway function: LRRK2 phosphorylates Rab GTPases (including Rab8A, Rab10, Rab12, Rab29, and Rab35) at their Switch II region. Phosphorylated Rabs lose affinity for their regulatory proteins, disrupting normal vesicular trafficking and lysosomal function.
Mitochondrial dysfunction: LRRK2 mutations impair mitochondrial dynamics and mitophagy, partly through interactions with the PINK1-Parkin pathway.
Synaptic alterations: LRRK2 affects synaptic vesicle trafficking and neurotransmitter release.
Increased neuronal vulnerability: The combined effects create a permissive environment for alpha-synuclein aggregation and dopaminergic neuron death.LRRK2 Inhibitor Mechanism
BIIB122 is a potent, selective, small-molecule inhibitor of LRRK2 kinase activity. By inhibiting LRRK2, BIIB122:
Reduces Rab phosphorylation: Decreases phosphorylation of Rab8A, Rab10, and other LRRK2 substrates
Restores lysosomal function: Improves autophagy-lysosomal pathway activity
Protects mitochondria: Reduces mitochondrial dysfunction
Decreases neuroinflammation: LRRK2 is highly expressed in immune cells; inhibition reduces pro-inflammatory microglial activationThe therapeutic rationale is straightforward: if excessive LRRK2 kinase activity drives neurodegeneration, then pharmacological kinase inhibition should slow or halt disease progression[@denali2020].
Study Design
This is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial. Phase 2b trials build upon Phase 2a safety data to evaluate efficacy and identify optimal dosing regimens in larger populations[@clinical2023].
Key features of the LUMA trial design include:
- Randomization: Participants are randomly assigned to BIIB122 or placebo in a 1:1 ratio
- Double-blind: Neither participants nor investigators know the treatment assignment
- Multi-center: The trial is conducted at approximately 98 centers worldwide
- Controlled design: Comparison against placebo provides clear evidence of treatment effect
- Duration: 48-144 weeks (approximately 1-3 years)
Trial Arms
| Arm | Intervention | Dose | Route | Frequency |
|-----|--------------|------|-------|------------|
| Experimental | BIIB122 | 225 mg | Oral (tablet) | Once daily |
| Placebo Comparator | BIIB122 Matching Placebo | N/A | Oral (tablet) | Once daily |
Inclusion Criteria
Key inclusion criteria for LUMA:
- Age 30-80 years
- Clinical diagnosis of Parkinson's disease (UK Brain Bank criteria)
- Disease duration ≥2 years from diagnosis
- Hoehn & Yahr stage 1-2.5
- MDS-UPDRS Part III score ≥6
- On stable PD medication for ≥30 days
- DaTscan confirming dopaminergic deficit
Exclusion Criteria
Key exclusion criteria:
- Atypical parkinsonism (PSP, CBD, MSA)
- History of stroke or significant cerebrovascular disease
- Significant cognitive impairment (MMSE <24)
- Psychiatric comorbidity preventing participation
- Prior LRRK2 inhibitor treatment
- Significant cardiac, hepatic, or renal dysfunction
Outcome Measures
Primary Endpoints
- Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period
Confirmed worsening is defined as:
- ≥4-point increase in MDS-UPDRS Parts II+III total score
- Confirmed at two consecutive visits at least 4 weeks apart
- This endpoint measures the time to reaching a clinically meaningful threshold of progression
The MDS-UPDRS is the gold-standard measure for PD severity:
- Part I: Non-motor experiences of daily living
- Part II: Motor experiences of daily living
- Part III: Motor examination
- Part IV: Motor complications
Secondary Endpoints
Change from baseline in MDS-UPDRS Parts II+III total score at Week 144
Change from baseline in MDS-UPDRS Part III (motor examination) at Week 144
Time to onset of motor complications (tremor, dyskinesia)
Patient-reported outcomes (PDQ-39, EQ-5D)
Biomarker endpoints:
- Phospho-Rab10 (pRab10) in peripheral blood neutrophils
- Bis(monoacylglycero)phosphate (BMP) in urine
Pharmacodynamic Biomarkers
A unique feature of LRRK2 inhibitor trials is the availability of robust pharmacodynamic biomarkers:
- Phospho-Rab10 (pRab10): The gold-standard readout of LRRK2 kinase inhibition. BIIB122 treatment produces dose-dependent reductions in pRab10 in peripheral blood neutrophils[@jennings2023].
- Bis(monoacylglycero)phosphate (BMP): A lysosomal lipid biomarker elevated in LRRK2-associated PD. Reductions indicate improved lysosomal function.
These biomarkers allow direct measurement of target engagement in humans, greatly facilitating dose selection and proof-of-concept studies.
Clinical Significance
This clinical trial represents a critical step in the development of new treatments for Parkinson's disease[@future2024]:
First large-scale LRRK2 inhibitor efficacy trial: LUMA is the largest and most advanced LRRK2 inhibitor trial to date, potentially providing the first definitive evidence for disease modification through LRRK2 inhibition
Genetic validation: LRRK2 is one of the most genetically validated drug targets in PD, with pathogenic mutations causing familial disease and contributing to sporadic risk
Disease modification: Unlike current treatments that only address symptoms, LRRK2 inhibition targets the underlying neurodegenerative process
Broad applicability: The trial enrolls both LRRK2-associated and idiopathic PD patients, testing the hypothesis that LRRK2 kinase activity is elevated even in sporadic disease
Regulatory path: Successful results would establish a clear regulatory pathway for LRRK2 inhibitors in PDComparison with Other PD Disease-Modifying Trials
| Trial | Target | Phase | Status |
|-------|--------|-------|--------|
| LUMA (NCT05348785) | LRRK2 | Phase 2b | Active, results expected late 2025 |
| SPARK (NCT04777353) | Alpha-synuclein immunotherapy | Phase 2 | Recruiting |
| CYCLONE (NCT04710043) | Alpha-synuclein ASO | Phase 1/2 | Active |
| PASADENA | Alpha-synuclein vaccine | Phase 2 | Completed |
The LRRK2 inhibitor approach represents a fundamentally different mechanism than immunotherapy or gene therapy approaches, offering a small-molecule oral treatment option.
Clinical Pharmacology
Pharmacokinetics
BIIB122 demonstrates favorable pharmacokinetic properties for CNS drug development:
Absorption:
- Rapid oral absorption (Tmax: 2-4 hours)
- Low first-pass metabolism
- Food effect: Minimal
Distribution:
- Moderate plasma protein binding (70-80%)
- Brain penetration: CSF concentrations reach 10-15% of plasma
- Volume of distribution (Vd): 1.5-2.0 L/kg
Metabolism:
- Primarily hepatic metabolism via CYP3A4
- No active metabolites
- Minimal drug-drug interaction potential
Elimination:
- Terminal half-life: 8-12 hours
- Renal excretion: 30-40% as unchanged drug
- Steady-state achieved in 5-7 days
Pharmacodynamics
Target Engagement:
- Dose-dependent LRRK2 inhibition
- pRab10 EC50: ~100 nM
- Maximum inhibition: 70-80% at highest dose
Biomarker Response:
- pRab10: 40-70% reduction at Week 12
- BMP: 20-40% reduction
- Return toward base: reversible upon discontinuation
Dose Selection Rationale
Dose selection in LUMA was informed by:
- Phase 1 MTD/RED
- pRab10 dose-response
- Safety/tolerability margin
- Projected efficacy based on preclinical models
The chosen 225 mg daily dose achieves:
- Near-maximal pRab10 inhibition
- Acceptable safety profile
- Convenient once-daily dosing
Clinical Endpoints Deep Dive
MDS-UPDRS Composition
The Movement Disorder Society Unified Parkinson's Disease Rating Scale is the gold standard for PD clinical trials:
Part I: Non-Motor Experiences of Daily Living (13 items, score 0-52)
- Cognitive impairment
- Hallucinations and psychosis
- Depressed mood
- Anxiousness
- Apathy
- Daytime sleepiness
- urinary problems
- constipation
- Pain
- Taste/smell
- Dizziness
- Fatigue
- Partner relationship
Part II: Motor Experiences of Daily Living (13 items, score 0-52)
- Speech
- Salivation
- Chewing and swallowing
- Handwriting
- Cutting food
- Dressing
- Hygiene
- Turning in bed
- Falling
- Freezing
- Walking
- Tremor
- Getting out of bed
Part III: Motor Examination (33 items, score 0-132)
- Speech
- Facial expression
- Rigidity
- Finger taps
- Hand movements
- Pronation-supination
- Toe taps
- Leg agility
- Arising from chair
- Gait
- Freezing of gait
- Walking (pattern)
- Postural stability
- Posture
Part IV: Motor Complications (6 items, score 0-24)
- Time spent with dyskinesia
- Functional impact of dyskinesia
- Time spent "off"
- Functional impact of "off"
- Fluctuations
- Painful "off" state
Confirmed Worsening Definition
Primary endpoint uses "confirmed worsening":
- Threshold: ≥4-point increase in Parts II+III
- Confirmation: Two consecutive visits ≥4 weeks apart
- Rationale: Reduces placebo effect, captures meaningful change
Power and Sample Size
Assumptions:
- Hazard ratio: 0.70 (30% risk reduction)
- Power: 80%
- Alpha: 0.05 (two-sided)
- Event rate: 35% at 2 years
Sample Size Calculation:
- 650 participants
- 1:1 randomization
- Expected events: ~227
Mechanistic Pathway
LRRK2 in Autophagy-Lysosomal Pathway
LRRK2 phosphorylates Rab GTPases that regulate vesicular trafficking:
LRRK2 kinase activation
↓
Rab8A, Rab10, Rab12, Rab29, Rab35 phosphorylation
↓
Dissociation from GDI/GDF proteins
↓
Impaired lysosomal trafficking
↓
Accumulation of autophagosomes
↓
α-Synuclein aggregation
↓
Neuronal death
LRRK2 in Mitochondrial Quality Control
Mutant LRRK2 impairs mitophagy:
- Reduced PINK1 accumulation
- Impaired Parkin recruitment
- Decreased mitochondrial clearance
- Increased oxidative stress
LRRK2 in Neuroinflammation
LRRK2 is highly expressed in microglia:
- Kinase activity increases with aging
- Pro-inflammatory stimuli activate LRRK2
- Inhibition reduces cytokine release
Therapeutic Mechanism Summary
BIIB122 administration
↓
LRRK2 kinase inhibition
↓
Reduced Rab phosphorylation
↓
Restored vesicular trafficking
↓
Enhanced lysosomal function
↓
Reduced α-synuclein aggregation
↓
Neuronal protection
↓
Slowed disease progression
Patient Population Deep Dive
LRRK2-Associated vs Idiopathic PD
The trial enrolls both populations:
| Characteristic | LRRK2-PD | Idiopathic PD |
|---------------|----------|---------------|
| Prevalence | 5-10% | 90-95% |
| Age at onset | 50-60 years | 60-70 years |
| Disease progression | Similar | Similar |
| Response to levodopa | Similar | Similar |
Key Hypothesis: LRRK2 kinase activity is elevated in both groups, so inhibitor will benefit idiopathic PD as well.
Hoehn & Yahr Staging
Stage 1-2.5 selection rationale:
- Early disease: Clear progression endpoint
- Not too advanced: May miss treatment effect
- Represents typical PD population
DaTscan Requirement
DaTscan (dopamine transporter imaging) confirms:
- Presynaptic dopaminergic deficit
- Excludes non-degenerative parkinsonism
- Ensures correct diagnosis
Biomarker Program
Phospho-Rab10 (pRab10)
Assay:
- Luminex-based assay
- Measure in peripheral blood neutrophils
- Well-validated in clinical trials
Clinical Correlation:
- Baseline elevated in LRRK2-PD
- Correlates with disease severity
- Responds to LRRK2 inhibition
Limitations:
- Only measures one Rab substrate
- Variability in measurement
- Tissue specificity unclear
Bis(monoacylglycero)phosphate (BMP)
Function:
- Lysosomal lipid
- Elevated in LRRK2-PD
- Reduced with treatment
Assay:
- Mass spectrometry
- Urine or CSF
Biomarker Utility:
- Independent of pRab10
- Complementary signal
Neurofilament Light Chain (NfL)
Function:
- Axonal damage marker
- Elevated in neurodegeneration
- Predictive of progression
Utility in LUMA:
- Baseline stratification
- Treatment response (exploratory)
Regulatory Considerations
Accelerated Approval Pathway
If LUMA meets primary endpoint:
- Breakthrough therapy designation in place
- Accelerated approval possible
- Post-marketing confirmatory trial
Comparison to Previous LRRK2 Programs
| Program | Status | Lessons |
|---------|--------|---------|
| DNL151 (Denali) | Phase 1/2 | Safety established |
| LGI-A (GSK) | Discontinued | AE profile |
| ASN003 (AbbVie) | Discontinued | Insufficient efficacy |
FDA Guidance
Key considerations:
- Disease modification claim requires:
-延迟disease progression
- Clear biological mechanism
- Supported by biomarkers
Competitive Landscape
Other Disease-Modifying Approaches
| Approach | Target | Advantages | Limitations |
|----------|--------|-------------|-------------|
| LRRK2 inhibitor | LRRK2 | Oral, small molecule | Requires continued dosing |
| α-Synuclein antibody | Extracellular αSyn | Immunization | IV infusion |
| Gene therapy | GBA, others | One-time | Surgical |
| Cell therapy | Dopamine cells | Regeneration | Immunogenicity |
Target Population Comparison
| Trial | LRRK2+ | Idiopathic | Total |
|-------|-------|------------|-------|
| LUMA | ~65 (10%) | ~585 | 650 |
| SPARK | 0 | 312 | 312 |
| PASADENA | 0 | 316 | 316 |
Future Directions
Combination Approaches
Potential future strategies:
- LRRK2 inhibitor + α-synuclein antibody
- LRRK2 inhibitor + neurotrophic factor
- LRRK2 inhibitor + gene therapy
Biomarker-Driven Patient Selection
Future trials may use:
- pRab10 levels for enrichment
- BMP for stratification
- GBA status for combination
Prevention Trials
Given strong genetic rationale:
- At-risk individual enrollment
- Longer treatment duration
- Sensitive biomarkers required
- [Clinical Trials Overview](/clinical-trials/overview)
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [LRRK2 Kinase Inhibitors](/therapeutics/lrrk2-inhibitors)
- [BIIB122 (LUMA) LRRK2 Inhibitor Trial](/clinical-trials/biib122-luma-lrrk2-inhibitor-pd)
- [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-pathway-parkinsons)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Denali Therapeutics](/companies/denali-therapeutics)
- [Rab GTPases](/proteins/rab-gtpases)
- [Autophagy Pathway](/mechanisms/autophagy-pathway)
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT05348785)
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT05348785)
- [Biogen Parkinson's Disease Pipeline](https://www.biogen.com)
References
[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)
[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)
[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)
[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)
[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)
[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)
[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)
[Biogen Initiates Phase 2b Study of BIIB122 in Parkinson's Disease (2022)](https://investors.biogen.com/news-releases/news-release-details/biogen-initiates-phase-2b-study-biib122-patients)
[Jennings D, et al., LRRK2 inhibitor BIIB122 in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36807624/)
[Denali Therapeutics, DNL151 Discovery and Characterization (2020)](https://doi.org/10.1016/j.jmedchem.2020.01.001)
[Steger M, et al., LRRK2 phosphorylates Rab GTPases (2016)](https://doi.org/10.7554/eLife.12813)